Alnylam announced on June 14, 2022, that its siRNA drug Amvuttra® (vutrisiran) was approved by the FDA for the treatment of polyneuropathy with hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
Roche has announced that the European Commission has granted approval for PiaSky® (crovalimab), an innovative recycling monoclonal antibody that targets the complement protein C5.
Aug 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
BioArctic AB revealed the publication of the findings from two phase-1 trials involving exidavnemab(ABBV-0805) in The Journal of Clinical Pharmacology.
Aug 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
SIFI revealed that the European Commission has granted approval for AKANTIOR® (polihexanide) for managing acanthamoeba keratitis (AK) in both adults and children aged 12 and over.